Relationships Between Advocacy Groups and Pharma
Applied Clinical Trials
Industry Standard Research
In a new report titled "Advocacy Groups: Enhancing Relationships and Patient Recruitment," Industry Standard Research interviewed 10 prominent patient advocacy groups to profile their involvement in clinical trials. All advocacy groups recognize clinical trials as a critical component of advancing knowledge. However, the degree of focus on educating patients about clinical trials and promoting participation in trials varies widely among organizations.
The organizations with a higher focus on clinical trials are the most involved in the clinical trial design process, frequently emphasizing the importance of patient relationships with industry, educating patients about trials, and partnering with pharma on trial-related endeavors.
Figure 1. Spectrum of clinical trial focus among advocacy groups.
Groups with a lower focus on clinical trials are not involved with the design of industry trials and do not have established processes to reach out to patients regarding trial education (general or related to specific trials). This is not to say that organizations not at the "high" end of the spectrum do not care about clinical trials. They do. They just have barriers to implementing a process encouraging patients to join industry's clinical trials that they have either been unable to or unwilling to cross.
—Industry Standard Research, www.ISRreports.com.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.
